Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.32
+0.07005.60%
Post-market: 1.32-0.0002-0.02%16:51 EDT
Volume:821.04K
Turnover:1.08M
Market Cap:95.44M
PE:-2.80
High:1.34
Open:1.27
Low:1.25
Close:1.25
52wk High:2.24
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:0.79
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:7.86
PE(LYR):-1.12

Loading ...

Biomea Fusion Price Target Announced at $10.00/Share by Brookline Capital

Dow Jones
·
Yesterday

Biomea Fusion Shares Fall After Terminating Proposed Public Offering

MT Newswires Live
·
Sep 24

Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next

TIPRANKS
·
Sep 24

Biomea Fusion Updates Timeline for BMF-650 Phase I Data

TIPRANKS
·
Sep 23

Biomea Fusion announces offering of common stock and warrants, no amount given

TIPRANKS
·
Sep 23

Biomea Fusion Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants

Reuters
·
Sep 23

Biomea Fusion Announces Proposed Public Offering of Securities

THOMSON REUTERS
·
Sep 23

Biomea Fusion - Topline Results from Phase I Glp-131 Trial for Bmf-650 Expected in October 2026 - SEC Filing

THOMSON REUTERS
·
Sep 23

Biomea Fusion to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 03

Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next

TIPRANKS
·
Aug 29

Biomea Shares Rise After Completing Enrollment in Diabetes Trial

MT Newswires Live
·
Aug 25

Unusually active option classes on open August 24th

TIPRANKS
·
Aug 24

Biomea Fusion completes enrollment in COVALENT-211 trial

TIPRANKS
·
Aug 24

Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027

THOMSON REUTERS
·
Aug 24

Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

THOMSON REUTERS
·
Aug 24

Biomea Fusion doses first patient in OPAL study

TIPRANKS
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Biomea Fusion (BMEA)

TIPRANKS
·
Aug 13

Biomea Fusion Doses First Patient in OPAL Trial of Icovamenib Plus Semaglutide for Obesity

Reuters
·
Aug 13

Biomea Fusion Announces First Patient Dosed in Opal Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

THOMSON REUTERS
·
Aug 13

Citi adds ‘upside 90-day catalyst watch’ on Biomea into GLP-1 data

TIPRANKS
·
Aug 11